Effects of zofenopril on myocardial ischemia in post–myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)–ISCHEMIA study
Authors:
- Claudio BorghiClaudio Borghi
- Ettore AmbrosioniEAEttore Ambrosioni
- 1 March 2007
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 153 (3) , 445.e7-445.e14
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk PopulationsAnnals of Pharmacotherapy, 2005
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockersAmerican Heart Journal, 2004
- Is angiotensin-converting enzyme inhibitor useful in a Japanese population for secondary prevention after acute myocardial infarction? A final report of the Japanese Acute Myocardial Infarction Prospective (JAMP) studyAmerican Heart Journal, 2004
- Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of CardiologyEuropean Heart Journal, 2004
- Effects of angiotensin-converting enzyme inhibition on transient ischemiaJACC, 2003
- Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 2003
- New evidence on the importance of the renin???angiotensin system in the treatment of higher-risk patients with hypertensionJournal Of Hypertension, 2003
- Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular diseaseThe American Journal of Medicine, 2002
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000